Two Companies, One Long-Term Vision

From Hyderabad to the Frontiers of Science: The Story of Atomic Cubit and Quantamathical

Although Atomic Cubit and Quantamathical operate in distinct domains, they are united by a common philosophy.

Both companies are built around the idea that advanced computation can unlock new scientific possibilities.

Quantamathical focuses on applying computational intelligence to real-world healthcare challenges.

Part -2

Atomic Cubit focuses on building computational infrastructure

Together, Naidu Nikhil Bhushan, Chief Executive Officer, and Palle Sai Tilak, Chief Technology Officer represent a unique combination of foundational technology development and practical scientific application. The founders believe that future advances in quantum computing could eventually transform molecular simulation, materials science, drug design, optimization, and artificial intelligence. By building expertise in both quantum infrastructure and scientific applications, they hope to position themselves at the intersection of two transformative technological trends.

Recognition and Growing Momentum

An important milestone in Quantamathical’s journey came through recognition by the Department for Promotion of Industry and Internal Trade (DPIIT) under the Startup India initiative. The recognition validates the innovative nature of the company’s work and provides access to opportunities within India’s startup ecosystem. For the founders, however, recognition is not the endpoint.

It is merely the beginning.

The next phase of growth will require expanded research infrastructure, specialized talent, strategic partnerships, and sustained investment. The founders are actively exploring collaborations with pharmaceutical organizations, academic institutions, researchers, and industry experts who share their long-term vision. They are also evaluating opportunities available through emerging quantum initiatives, including the Andhra Pradesh government’s efforts to establish a globally competitive quantum ecosystem. “Scientific innovation requires collaboration,” says Nikhil. “No breakthrough happens in isolation.”

The Economic Significance of Their Mission

The sectors targeted by Atomic Cubit and Quantamathical represent enormous global opportunities. Quantum computing is expected to influence industries worth trillions of dollars over the coming decades, including pharmaceuticals, telecommunications, finance, cybersecurity, logistics, and advanced manufacturing. Similarly, the pharmaceutical industry continues to represent one of the world’s largest research-driven sectors, with global spending on drug discovery and development reaching hundreds of billions of dollars annually.

Success in either field could create substantial economic and societal value.Success across both could position India as a contributor to technologies that shape the future of science and industry. The founders believe this represents an opportunity for the country to move beyond technology adoption and toward technology creation. “We should not only consume future technologies,” says Sai Tilak. “We should participate in building them.”

Looking Ahead

The road ahead remains challenging. Deep-tech ventures require patience, investment, talent, and long-term commitment. Yet the founders remain optimistic. Their immediate priorities include advancing quantum processor development at Atomic Cubit, strengthening scientific research at Quantamathical, pursuing strategic collaborations, and expanding their research capabilities. They are also seeking mentors, investors, pharmaceutical partners, and research collaborators who believe in India’s potential to become a global leader in advanced science and technology. With the right support, they believe both companies can contribute meaningful innovations to global scientific progress.

Inspiring the Next Generation

Perhaps the most important aspect of their story is not the technology itself but the message it sends. The founders want students, researchers, engineers, and aspiring entrepreneurs across India to recognize that ambitious scientific goals are worth pursuing. World-class innovation does not require perfect conditions. It requires curiosity, persistence, and the courage to work on difficult problems. “We want young Indians to believe that they can build technologies that matter globally,” says Nikhil.

Sai Tilak shares the same vision.

“The future will belong to those willing to solve hard problems. If our journey inspires even a few young scientists or entrepreneurs to pursue deep-tech innovation, that would be one of our greatest achievements.” From a small office in Hyderabad, two founders are attempting something few dare to pursue: building technologies that could shape the future of computation and healthcare.

Quanta Mathical Hits Key Milestone with First ERK2 Inhibitor Candidate

Quanta Mathical recently completed and released its first computational drug discovery study, focused on a novel ERK2 inhibitor candidate. The research evaluated the molecule across multiple parameters including target binding, drug-likeness, safety, pharmacokinetics, and synthesizability. The candidate demonstrated favorable computational results, passed key drug-likeness filters, showed a clean structural safety profile, and presented a viable path toward laboratory synthesis and experimental validation. This milestone represents QuantaMathical’s first step toward building a next-generation computational drug discovery platform in India.

Scaling India’s Deep-Tech Ecosystem

Business Perspective: The global pharmaceutical industry is valued at over $1.7 trillion, while the demand for faster and more efficient drug discovery continues to grow. By combining advanced computational chemistry through QuantaMathical with the future quantum computing capabilities being developed by Atomic Cubit, these Hyderabad-based startups aim to position India as a contributor to both the global drug discovery and quantum technology ecosystems. Their long-term vision is to reduce the cost and time required to discover new medicines while creating world-class deep-tech intellectual property from India.

El Rado Molecular Intelligence Platform

Investor-Grade Strategic Dossier for Quantamathical

El Rado is envisioned as a molecular intelligence platform that combines computational chemistry, AI-assisted molecular design, optimization workflows, simulation, and future quantum acceleration. The goal is to reduce the cost, time, and uncertainty associated with discovering and optimizing molecular candidates. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Vision and Mission

Predict molecular reality before physical experimentation. Mission: Build sovereign molecular intelligence capabilities originating from India and serving global markets. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Why Molecular Intelligence Matters –Traditional R&D relies on expensive screening and laboratory iteration. Molecular intelligence seeks to prioritize the most promising candidates digitally before resources are committed. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Technology Architecture and Core layers: Molecule generation, molecular optimization, scoring, ranking, simulation, explainability, workflow orchestration, and future quantum integration. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

El Rado Capability Map

Candidate generation, molecular property prediction, prioritization, workflow automation, research acceleration, and decision support. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Drug Discovery Market – Applications include oncology, infectious disease, rare disease, metabolic disorders, CNS disorders, and drug repurposing. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Peptide Discovery -Design and optimization of therapeutic peptides, delivery peptides, and antimicrobial peptides. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Protein Engineering -Future expansion into protein engineering, enzyme design, and synthetic biology workflows. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Materials Discovery -Discovery of battery materials, catalysts, semiconductors, superconductors, polymers, and advanced materials. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Quantum Materials -Potential discovery of materials relevant to future quantum processors and cryogenic systems. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Climate Technology -Carbon capture materials, sustainable chemistry, green catalysts, and environmental remediation. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Agricultural Chemistry -Crop-protection molecules, bio-pesticides, and growth regulators. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Cosmetic Chemistry– Anti-aging compounds, skincare molecules, UV protection, and hair-care chemistry. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Flavor and Fragrance -Design and optimization of flavor and fragrance molecules. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Molecular Property Prediction – Prediction of toxicity, solubility, stability, permeability, manufacturability, and binding affinity. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Digital Molecular Twins -Long-term vision to simulate molecules, reactions, and biological systems digitally. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Disease Biology-Future prediction of pathways, biomarkers, and therapeutic targets. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Revenue Models -SaaS subscriptions, enterprise licensing, APIs, molecule design services, government contracts, and strategic partnerships. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Customer Segments– Pharma, biotech, CROs, specialty chemicals, universities, government labs, materials companies, and climate-tech firms. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Competitive Landscape-Competes broadly with computational chemistry, AI drug discovery, and molecular design platforms. Differentiation comes from platform breadth and future quantum integration. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Defensibility-Workflow IP, validation pipelines, domain expertise, proprietary data accumulation, and sovereign technology positioning. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Quantamathical and Atomic Cubit

Potential long-term ecosystem where Atomic Cubit provides quantum hardware and El Rado provides molecular workloads. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves. India Opportunity-Opportunity to contribute to India’s sovereign capabilities in molecular science and future quantum-enabled research. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves. Go-To-Market Strategy- Begin with pilots, design partnerships, academic collaborations, and targeted enterprise engagements. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Five-Year Roadmap -Year 1–2: Drug Discovery-Year 2–3: Peptides and Proteins-Year 3–4: Materials Discovery-Year 4–5: Molecular Intelligence Expansion -Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves. Risk Assessment: Scientific validation, commercialization risk, regulatory challenges, customer adoption, computational costs, and execution complexity. Strategic note: his section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves. Funding Strategy-Government grants, startup programs, strategic partnerships, angel investors, venture capital, and research collaborations. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

TAM/SAM/SOM Framework -A future fundraising version should estimate addressable opportunities across pharmaceuticals, materials science, industrial chemistry, agriculture, and climate technology. Strategic note: This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Global Expansion Strategy- Target North America, Europe, Middle East, and Asia-Pacific through partnerships and enterprise programs. This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Long-Term End State – The ultimate objective is a Molecular Intelligence Company capable of predicting, optimizing, and simulating molecular systems across multiple industries. This section should be supported by future validation data, customer discovery, research publications, and commercialization milestones as the platform evolves.

Appendix A: 35+ Potential Predictive Technology Verticals

* Drug Discovery * Rare Disease Therapeutics* Peptide Design * Protein Engineering * Enzyme Optimization * Vaccine Design * Agricultural Molecules * Crop Protection * Bio-Pesticides * Cosmetic Chemistry * Anti-Aging Molecules * Hair Care Chemistry *  Fragrance Design * Flavor Design * Catalyst Discovery * Industrial Chemistry * Green Chemistry * Carbon Capture Materials * Battery Materials * Semiconductor Materials * Quantum Materials * Superconducting Materials * Photonic Materials * Hydrogen Storage * Advanced Polymers * Environmental Chemistry * Water Treatment Chemistry * Toxicity Prediction * Molecular Property APIs * Digital Molecular Twins * Disease Biology * Biomarker Discovery * Research-as-a-Service * Simulation Platforms * Materials Optimization.

Their journey is still unfolding.

But through Atomic Cubit and Quantamathical, they are already demonstrating that world-class scientific ambition can emerge from India—and that the next generation of breakthrough technologies may carry an Indian signature. “The anomalies in NEET were first exposed by a student in Patna. Meanwhile, research by software engineers Nikhil and Sai could potentially drive a major leap forward in the pharmaceutical sector—let’s hope it delivers results.”